tradingkey.logo

Centessa Pharmaceuticals PLC

CNTA
25.680USD
0.000
Close 12/24, 16:00ETQuotes delayed by 15 min
3.45BMarket Cap
LossP/E TTM

Centessa Pharmaceuticals PLC

25.680
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Centessa Pharmaceuticals PLC

Currency: USD Updated: 2025-12-24

Key Insights

Centessa Pharmaceuticals PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.08.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Centessa Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking
42 / 404
Overall Ranking
121 / 4562
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 15 analysts
Buy
Current Rating
37.077
Target Price
+25.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Centessa Pharmaceuticals PLC Highlights

StrengthsRisks
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Undervalued
The company’s latest PE is -13.54, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 133.92M shares, increasing 0.01% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 4.37K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of Centessa Pharmaceuticals PLC is 7.62, ranking 97/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score
7.62
Change
0

Financials

6.68

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.87

Operational Efficiency

8.98

Growth Potential

6.36

Shareholder Returns

7.20

Centessa Pharmaceuticals PLC's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of Centessa Pharmaceuticals PLC is 6.80, ranking 227/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.54, which is -90.33% below the recent high of -1.31 and -16.47% above the recent low of -15.77.

Score

Industry at a Glance

Previous score
6.80
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 42/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of Centessa Pharmaceuticals PLC is 8.67, ranking 72/404 in the Biotechnology & Medical Research industry. The average price target for Centessa Pharmaceuticals PLC is 36.00, with a high of 52.00 and a low of 30.00.

Score

Industry at a Glance

Previous score
8.67
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts
Buy
Current Rating
37.077
Target Price
+25.68%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Centessa Pharmaceuticals PLC
CNTA
15
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of Centessa Pharmaceuticals PLC is 7.08, ranking 160/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.45 and the support level at 23.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.94
Change
0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.861
Neutral
RSI(14)
44.534
Neutral
STOCH(KDJ)(9,3,3)
31.092
Buy
ATR(14)
1.270
High Vlolatility
CCI(14)
-49.823
Neutral
Williams %R
76.443
Sell
TRIX(12,20)
-0.227
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
25.204
Buy
MA10
25.656
Buy
MA20
27.388
Sell
MA50
25.876
Sell
MA100
22.942
Buy
MA200
18.342
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of Centessa Pharmaceuticals PLC is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.37%, representing a quarter-over-quarter decrease of 8.92%. The largest institutional shareholder is PRFDX, holding a total of 4.80M shares, representing 3.29% of shares outstanding, with 17.74% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Medicxi Ventures (UK) LLP
19.96M
--
Avoro Capital Advisors LLC
5.00M
+23.46%
Adage Capital Management, L.P.
8.40M
+20.84%
Index Ventures SA
9.96M
--
General Atlantic LLC
9.68M
--
Fidelity Management & Research Company LLC
3.83M
--
Janus Henderson Investors
6.53M
+10.30%
T. Rowe Price Associates, Inc.
Star Investors
5.91M
+10.59%
Farallon Capital Management, L.L.C.
4.53M
+4.50%
VV Manager LLC
3.93M
--
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of Centessa Pharmaceuticals PLC is 5.10, ranking 64/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.10
Change
0
Beta vs S&P 500 index
1.58
VaR
--
240-Day Maximum Drawdown
+43.72%
240-Day Volatility
+77.07%

Return

Best Daily Return
60 days
+18.46%
120 days
+18.46%
5 years
--
Worst Daily Return
60 days
-8.08%
120 days
-8.08%
5 years
--
Sharpe Ratio
60 days
+0.64
120 days
+2.35
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+43.72%
3 years
+43.72%
5 years
--
Return-to-Drawdown Ratio
240 days
+1.47
3 years
+4.62
5 years
--
Skewness
240 days
+0.79
3 years
+0.47
5 years
--

Volatility

Realised Volatility
240 days
+77.07%
5 years
--
Standardised True Range
240 days
+4.17%
5 years
--
Downside Risk-Adjusted Return
120 days
+495.81%
240 days
+495.81%
Maximum Daily Upside Volatility
60 days
+47.98%
Maximum Daily Downside Volatility
60 days
+62.69%

Liquidity

Average Turnover Rate
60 days
+0.83%
120 days
+0.75%
5 years
--
Turnover Deviation
20 days
+60.72%
60 days
+76.35%
120 days
+60.06%

Peer Comparison

Biotechnology & Medical Research
Centessa Pharmaceuticals PLC
Centessa Pharmaceuticals PLC
CNTA
7.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Centessa Pharmaceuticals PLC?

The TradingKey Stock Score provides a comprehensive assessment of Centessa Pharmaceuticals PLC based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Centessa Pharmaceuticals PLC’s performance and outlook.

How do we generate the financial health score of Centessa Pharmaceuticals PLC?

To generate the financial health score of Centessa Pharmaceuticals PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Centessa Pharmaceuticals PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Centessa Pharmaceuticals PLC.

How do we generate the company valuation score of Centessa Pharmaceuticals PLC?

To generate the company valuation score of Centessa Pharmaceuticals PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Centessa Pharmaceuticals PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Centessa Pharmaceuticals PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Centessa Pharmaceuticals PLC.

How do we generate the earnings forecast score of Centessa Pharmaceuticals PLC?

To calculate the earnings forecast score of Centessa Pharmaceuticals PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Centessa Pharmaceuticals PLC’s future.

How do we generate the price momentum score of Centessa Pharmaceuticals PLC?

When generating the price momentum score for Centessa Pharmaceuticals PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Centessa Pharmaceuticals PLC’s prices. A higher score indicates a more stable short-term price trend for Centessa Pharmaceuticals PLC.

How do we generate the institutional confidence score of Centessa Pharmaceuticals PLC?

To generate the institutional confidence score of Centessa Pharmaceuticals PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Centessa Pharmaceuticals PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Centessa Pharmaceuticals PLC.

How do we generate the risk management score of Centessa Pharmaceuticals PLC?

To assess the risk management score of Centessa Pharmaceuticals PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Centessa Pharmaceuticals PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Centessa Pharmaceuticals PLC.
KeyAI